-
-
-
-
-
-
-
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
-
-
-
-
-
-
-
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Reports Prelim. Data from Phase 1 Clinical Trial of SPR206; Will Advance Program with Alliance Partners Everest Medicines & DoD
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Secures $54M Award from BARDA and DTRA to Support SPR994 Development
-
-
-
-
-
-
-
SmartPros Reports Third Quarter 2015 Financial Results
-
-
-
1,168,812 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

